Published · Aurelis Peptides
BPC-157 and TB-500 often appear together when people search for recovery peptides. They are different materials, and the studies behind their names examine different cells and tissues. This comparison helps you move from a familiar name to a clearer understanding of the research and the product listing.
Start with three questions: which molecule was studied, what was measured, and what does the catalogue entry contain? Answering those questions makes a comparison more useful than choosing a name from a headline.
BPC-157 vs TB-500 at a glance
| Compare | BPC-157 | TB-500 |
|---|---|---|
| Name and identity | A synthetic 15-amino-acid peptide | A thymosin-beta-4-related name; confirm the actual sequence |
| Research discussed here | Rat tendon cells: movement, outgrowth and survival under stress | Analytical identification of a TB-500 fragment; separate full-length thymosin beta-4 tissue studies |
| Aurelis listed content | 10 mg per unit | 10 mg per unit |
| Related blend | Wolverine 20 mg: BPC 10 mg + TB 10 mg | |
The table separates a product name from a research result. In particular, a paper about full-length thymosin beta-4 is not automatically a paper about the material labelled TB-500. The primary sources below explain why that distinction matters.
BPC-157: tendon cells and repair research
BPC-157 is a 15-amino-acid peptide. A 2011 study by Chang and colleagues examined tendon tissue taken from rats and tendon fibroblasts grown in the laboratory. Fibroblasts are cells involved in the tissue’s supporting structure.
The researchers observed faster cell outgrowth from tendon samples. Treated cells also moved and spread more readily, and more survived an experimental oxidative stress. The study did not find a direct increase in the proliferation of the cultured tendon fibroblasts. Movement, survival and multiplication are different measurements.
This explains the interest in BPC-157 within tendon and recovery research. The study investigated cell behaviour in laboratory conditions; it did not measure recovery time in people. Read the primary tendon-cell study.
TB-500 and thymosin beta-4: check the identity
The TB-500 name needs a closer look. A 2012 analytical study by Ho and colleagues identified a preparation containing an N-acetylated seven-amino-acid fragment, LKKTETQ, from a region of thymosin beta-4.
The team developed a method to detect that fragment and its breakdown products in horse urine and plasma. This was an identification study. It did not test human recovery benefits. Read the TB-500 identification paper.
For an Aurelis TB-500 enquiry, request the selected material’s sequence and identity records. The catalogue name alone does not specify whether a material matches the fragment in that paper or a different thymosin-beta-4-related specification.
What did thymosin beta-4 tissue studies find?
Two earlier papers help explain why thymosin beta-4 appears in tissue-repair discussions. These papers studied thymosin beta-4, rather than the TB-500 preparation identified in the 2012 analysis.
In 1997, Malinda and colleagues studied cells that line blood vessels. Their laboratory experiments showed greater movement towards thymosin beta-4 and faster movement into a scratched area of a cell layer. Cell movement was the endpoint being measured. Read the endothelial-cell migration study.
In a 1999 rat skin-wound study, the same research group reported faster resurfacing of wounds, greater wound contraction, increased collagen deposition and new blood-vessel formation. They also observed increased movement of skin cells in a separate laboratory assay. Those results describe the rats and cell experiments in that paper. Read the rat wound-repair study.
Which comparison is useful for your enquiry?
For tendon-cell behaviour, begin with the BPC-157 paper. For the TB-500 name, begin with molecular identity. Then read a thymosin beta-4 paper with its actual test material and tissue model in view.
These selected studies do not compare BPC-157 and TB-500 head to head. A tendon-cell experiment and a skin-wound experiment answer different questions. Keeping those differences visible gives you a more precise basis for discussing research materials.
10 mg listings and the Wolverine blend
Aurelis lists BPC-157 and TB-500 at 10 mg each per unit. Matching amounts do not make the molecules interchangeable. These figures describe listed content, rather than a dose, concentration or measure of biological activity.
Wolverine is listed at 20 mg, with BPC 10 mg + TB 10 mg. That is a catalogue composition. The individual studies above did not evaluate this blend. Confirm both ingredient identities and their amounts together when requesting its batch specification.
Prepare a clear product enquiry
Include the compound or blend name, listed content, desired presentation and destination country. Aurelis enquiries cover Australia, Canada and the USA. Ask about the available vial or kit presentation for your chosen entry, and request documents that identify the same material and batch.
Open the BPC-157 profile, TB-500 profile or blend comparison for more catalogue detail. Our quality guide explains documentation, and the format guide covers vials and kits. Send a BPC-157 or TB-500 enquiry with the specification you want to discuss.
Primary research sources
- Chang et al. · Journal of Applied Physiology · 2011 — rat tendon samples and cultured fibroblasts.
- Ho et al. · Journal of Chromatography A · 2012 — TB-500 fragment identification and detection in horse samples.
- Malinda et al. · FASEB Journal · 1997 — thymosin beta-4 and blood-vessel cell migration.
- Malinda et al. · Journal of Investigative Dermatology · 1999 — thymosin beta-4 in rat skin wounds and skin-cell migration.